サウジアラビアのNGHA医療システムにおける2型糖尿病薬の導入:現在の傾向

Mesnad S Alyabsi^1,2, Lolwah Almousa^1,3, Anwar H Alqarni^1,2

¹Department of Population Health, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.

Current therapeutic research, clinical and experimental

|September 2, 2025

まとめ

2型糖尿病 (T2DM) の治療パターンは進化しています. この研究では,GLP-1受容体アゴニストやSGLT-2阻害剤などの新薬の増加が確認され,更新されたガイドラインを反映しています.

科学分野:

内分泌学
薬理学について
公衆衛生

背景:

2型糖尿病 (T2DM) 管理ガイドラインは継続的に更新され,臨床実務に影響を与えています.
T2DMの治療パターンは,これらのガイドラインの変更に対応して変化を示しています.

研究の目的:

T2DM患者における様々な抗糖尿病薬の投与開始頻度を決定する.
異なる初期治療戦略に関連した患者の特徴を分析する.

主な方法:

ナショナル・ガード・ヘルス・アフェアーズの電子医療記録を用いた横断的な研究です
2018年1月から2022年5月の間に抗糖尿病療法を開始した433人のT2DM患者のデータを分析した.
メトホルミン,インスリン,スルフォニル尿素,チアゾリジンジオン,DPP-4阻害剤,GLP- 1RAおよびSGLT- 2阻害剤の発生率を評価した.

主要な成果:

T2DM患者のほとんどは女性 (55. 66%) で,肥満患者 (61. 20%) で,平均年齢は53. 29歳でした.
モノセラピーは最も一般的な初期アプローチ (66. 28%) で,インスリンが最も多く処方されました (29. 10%).
メトホルミンは,全体的に最も多く開始された薬剤でした (37. 12%). 2021年に新たに診断された患者のGLP-1RA (8. 70%) とSGLT-2阻害剤 (11. 11%) の顕著な増加が観察されました.

結論:

更新されたT2DM管理ガイドラインに沿って,新しい抗糖尿病薬の開始が増加しました.
最適な患者管理のためのこれらの新薬の利点を完全に理解するには,さらなる研究が必要です.

キーワード:

抗糖尿病薬糖尿病メリット薬学流行病学サウジアラビア

さらに関連する動画

07:22

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

370

05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

347

関連する概念動画

01:22

Diabetes Mellitus: Type 2 and Gestational

2.9K

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...

2.9K

01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

288

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...

288

01:15

Diabetes: Management and Pharmacotherapy

354

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...

354

01:22

Diabetes Mellitus: Overview and Type I Subtype

3.2K

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...

3.2K

01:24

Glucagon-like Receptor Agonists

416

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

416

01:20

Pathophysiology of Diabetes

1.2K

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...